Schizophrenia

     expertise

specialized expertise

At CRC, we deliver precise, reliable data for schizophrenia research, fast. Our expertise ensures that the data you receive is not only accurate but also actionable—helping you make critical decisions quickly. With a dedicated team of experts, we’re committed to supporting every phase of your research. From trial setup to final analysis, we’re here to ensure your study moves forward smoothly. Trust us to support your mission with the urgency and precision it deserves.

2

recent FDA approvals for schizophrenia treatments

supported

20+

Schizophrenia

PROGRAMS, PHASE I-IV

30+

YEAR PARTNERSHIP WITH LEADING KOLs in schizophrenia

endpoint expertise including:

SYMPTOM SEVERITY

& PSYCHOPATHOLOGY

PANSS

BARS

AIMS

SAS

NSA-16

EMA

COGNITIVE & FUNCTIONAL

MCCB

BACS

VRFCAT

WCST

SCoRS

Biomarker Expertise

CSF

Electrophysiology

Neuroimaging


Relevant CRC

      case Studies

A group of business people are sitting at a table with their fists in the air.

IND to FDA Approval

A man is getting a vaccine in his arm.

FDA Approval of Novel Formulation

A group of doctors and nurses are standing in a room talking to each other.

FPI 6 Weeks from Written Award

RECENT CRC

      RELATED PUBLICATIONS

A man is holding his head in pain while sitting on a couch.

Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers

Schizophrenia Research, 2023


Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults with Schizophrenia or Schizoaffective Disorder

The Journal of Clinical Psychiatry, 2023


Igalmi™ – FDA Approval, from IND to NDA, 2022